Drug Profile
Research programme: ultra fast-acting insulin aspart - Albireo Pharma/HEC Pharm
Alternative Names: Insulin aspart 30 - Albireo Pharma/HEC Pharm; Ultra-rapid-acting insulin aspart - Albireo Pharma/HECLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Insulins; Peptides
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 28 Dec 2019 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
- 22 Apr 2014 Early research in Diabetes mellitus in USA (Parenteral)